---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014815"
form_type: "8-K"
ticker: "CURX"
cik: "0002025942"
company_name: "Curanex Pharmaceuticals Inc"
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:53:37.348462+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market

## Summary
- Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).
- Global cancer cachexia market was $2.54B in 2024, projected to reach $3.90B by 2033; no approved therapies in US.
- Lead program Phyto-N remains in preclinical for ulcerative colitis; Company evaluating further development opportunities in cachexia.
- Management sees this as key step in evolving into a broader therapeutics company.

## SEC filing metadata
- accession: 0001493152-26-014815
- form_type: 8-K
- ticker: CURX
- cik: 0002025942
- company_name: Curanex Pharmaceuticals Inc
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2025942/000149315226014815/0001493152-26-014815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2025942/000149315226014815/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014815
- JSON: https://secwatch.observer/filing/0001493152-26-014815.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.